Information  X 
Enter a valid email address

Oxford BioDynamics (OBD)

  Print      Mail a friend

Tuesday 19 November, 2019

Oxford BioDynamics

Notice of Results

RNS Number : 8093T
Oxford BioDynamics PLC
19 November 2019
 

19 November 2019

OXFORD BIODYNAMICS PLC

("OBD" or the "Company" or the "Group")

 

Notice of results for the year ended 30 September 2019

 

 

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, expects to announce its full year results for the year ended 30 September 2019 on Tuesday 10 December 2019.

 

For further details please contact:

 

Oxford BioDynamics Plc                                                                                +44 (0)1865 518910

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

Shore Capital                                                                                                      +44 (0)20 7408 4090

Broker and Nominated Adviser

Stephane Auton

Edward Mansfield

 

FTI Consulting                                                                                                    +44 (0)20 3727 1000

Financial Public Relations Adviser

Brett Pollard

Natalie Garland-Collins

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORDVLFFKFFXFBF

a d v e r t i s e m e n t